These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 28335835)

  • 1. Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.
    Konstantinides SV; Vicaut E; Danays T; Becattini C; Bertoletti L; Beyer-Westendorf J; Bouvaist H; Couturaud F; Dellas C; Duerschmied D; Empen K; Ferrari E; Galiè N; Jiménez D; Kostrubiec M; Kozak M; Kupatt C; Lang IM; Lankeit M; Meneveau N; Palazzini M; Pruszczyk P; Rugolotto M; Salvi A; Sanchez O; Schellong S; Sobkowicz B; Meyer G
    J Am Coll Cardiol; 2017 Mar; 69(12):1536-1544. PubMed ID: 28335835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial.
    Barco S; Russo M; Vicaut E; Becattini C; Bertoletti L; Beyer-Westendorf J; Bouvaist H; Couturaud F; Danays T; Dellas C; Duerschmied D; Empen K; Ferrari E; Galiè N; Jiménez D; Klok FA; Kostrubiec M; Kozak M; Kupatt C; Lang IM; Lankeit M; Meneveau N; Palazzini M; Pruszczyk P; Rugolotto M; Salvi A; Sanchez O; Schellong S; Sobkowicz B; Meyer G; Konstantinides SV
    Clin Res Cardiol; 2019 Jul; 108(7):772-778. PubMed ID: 30564950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial.
    Steering Committee
    Am Heart J; 2012 Jan; 163(1):33-38.e1. PubMed ID: 22172434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial.
    Kline JA; Nordenholz KE; Courtney DM; Kabrhel C; Jones AE; Rondina MT; Diercks DB; Klinger JR; Hernandez J
    J Thromb Haemost; 2014 Apr; 12(4):459-68. PubMed ID: 24484241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolysis for patients with intermediate-risk pulmonary embolism.
    Meyer G; Vicaut E; Danays T; Agnelli G; Becattini C; Beyer-Westendorf J; Bluhmki E; Bouvaist H; Brenner B; Couturaud F; Dellas C; Empen K; Franca A; Galiè N; Geibel A; Goldhaber SZ; Jimenez D; Kozak M; Kupatt C; Kucher N; Lang IM; Lankeit M; Meneveau N; Pacouret G; Palazzini M; Petris A; Pruszczyk P; Rugolotto M; Salvi A; Schellong S; Sebbane M; Sobkowicz B; Stefanovic BS; Thiele H; Torbicki A; Verschuren F; Konstantinides SV;
    N Engl J Med; 2014 Apr; 370(15):1402-11. PubMed ID: 24716681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism.
    Becattini C; Agnelli G; Salvi A; Grifoni S; Pancaldi LG; Enea I; Balsemin F; Campanini M; Ghirarduzzi A; Casazza F;
    Thromb Res; 2010 Mar; 125(3):e82-6. PubMed ID: 19833379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial.
    Sanchez O; Charles-Nelson A; Ageno W; Barco S; Binder H; Chatellier G; Duerschmied D; Empen K; Ferreira M; Girard P; Huisman MV; Jiménez D; Katsahian S; Kozak M; Lankeit M; Meneveau N; Pruszczyk P; Petris A; Righini M; Rosenkranz S; Schellong S; Stefanovic B; Verhamme P; de Wit K; Vicaut E; Zirlik A; Konstantinides SV; Meyer G;
    Thromb Haemost; 2022 May; 122(5):857-866. PubMed ID: 34560806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical audit of thrombolytic therapy in patients with normotensive pulmonary embolism and intermediate risk.
    Nobre C; Mesquita D; Thomas B; Ponte T; Santos L; Tavares J
    Acute Card Care; 2014 Jun; 16(2):63-6. PubMed ID: 24617753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy.
    Meneveau N; Ming LP; Séronde MF; Mersin N; Schiele F; Caulfield F; Bernard Y; Bassand JP
    Eur Heart J; 2003 Aug; 24(15):1447-54. PubMed ID: 12909074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical update on thrombolytic use in pulmonary embolism: A focus on intermediate-risk patients.
    Eberle H; Lyn R; Knight T; Hodge E; Daley M
    Am J Health Syst Pharm; 2018 Sep; 75(17):1275-1285. PubMed ID: 29895520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic therapy for submassive pulmonary embolism.
    Lankeit M; Konstantinides S
    Best Pract Res Clin Haematol; 2012 Sep; 25(3):379-89. PubMed ID: 22959553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of early complications and late consequences after acute pulmonary embolism: Focus on reperfusion techniques.
    Konstantinides SV; Barco S
    Thromb Res; 2018 Apr; 164():163-169. PubMed ID: 28595772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Rescue Thrombolysis in Cardiac Arrest Secondary to Suspected or Confirmed Pulmonary Embolism.
    Summers K; Schultheis J; Raiff D; Dahhan T
    Ann Pharmacother; 2019 Jul; 53(7):711-715. PubMed ID: 30700101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin.
    Fasullo S; Scalzo S; Maringhini G; Ganci F; Cannizzaro S; Basile I; Cangemi D; Terrazzino G; Parrinello G; Sarullo FM; Baglini R; Paterna S; Di Pasquale P
    Am J Med Sci; 2011 Jan; 341(1):33-9. PubMed ID: 20890176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Thrombolysis Therapy is Associated With Improved Outcomes Among Patients With Acute Pulmonary Embolism and Respiratory Failure.
    Koslow M; Epstein Shochet G; Fenadka F; Neuman Y; Osadchy A; Shitrit D
    Am J Med Sci; 2020 Aug; 360(2):129-136. PubMed ID: 32466857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolysis in submassive pulmonary embolism, prudent or puerile?
    Rehman A; Yousaf S; Chugh A
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23354859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of unsuccessful thrombolysis in acute massive pulmonary embolism.
    Meneveau N; Séronde MF; Blonde MC; Legalery P; Didier-Petit K; Briand F; Caulfield F; Schiele F; Bernard Y; Bassand JP
    Chest; 2006 Apr; 129(4):1043-50. PubMed ID: 16608956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study.
    Klok FA; Piazza G; Sharp ASP; Ní Ainle F; Jaff MR; Chauhan N; Patel B; Barco S; Goldhaber SZ; Kucher N; Lang IM; Schmidtmann I; Sterling KM; Becker D; Martin N; Rosenfield K; Konstantinides SV
    Am Heart J; 2022 Sep; 251():43-53. PubMed ID: 35588898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing the management of acute intermediate-high-risk pulmonary embolism: The enduring legacy of Professor Guy Meyer.
    Konstantinides SV; Sanchez O; Goldhaber SZ; Meneveau N
    Presse Med; 2024 Sep; 53(3):104248. PubMed ID: 39244019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Thrombolysis, Catheter-Directed Thrombolysis, and Anticoagulation for Intermediate-risk Pulmonary Embolism: A Simulation Modeling Analysis.
    Kabrhel C; Ali A; Choi JG; Hur C
    Acad Emerg Med; 2017 Oct; 24(10):1235-1243. PubMed ID: 28650086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.